Harbor Capital Advisors Inc. Sells 35,407 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Harbor Capital Advisors Inc. decreased its stake in shares of Castle Biosciences, Inc. (NASDAQ:CSTL) by 23.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 118,500 shares of the company’s stock after selling 35,407 shares during the quarter. Harbor Capital Advisors Inc. owned 0.42% of Castle Biosciences worth $3,158,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Quest Partners LLC raised its holdings in Castle Biosciences by 54.4% in the 3rd quarter. Quest Partners LLC now owns 4,318 shares of the company’s stock valued at $123,000 after acquiring an additional 1,522 shares in the last quarter. US Bancorp DE raised its stake in shares of Castle Biosciences by 1,889.2% in the third quarter. US Bancorp DE now owns 4,615 shares of the company’s stock valued at $132,000 after purchasing an additional 4,383 shares in the last quarter. Point72 DIFC Ltd bought a new position in shares of Castle Biosciences during the 3rd quarter worth about $140,000. Assetmark Inc. boosted its position in shares of Castle Biosciences by 16.8% during the 3rd quarter. Assetmark Inc. now owns 5,212 shares of the company’s stock valued at $149,000 after acquiring an additional 748 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. increased its stake in Castle Biosciences by 64.6% in the third quarter. China Universal Asset Management Co. Ltd. now owns 5,335 shares of the company’s stock valued at $152,000 after acquiring an additional 2,093 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.

Analysts Set New Price Targets

CSTL has been the topic of several analyst reports. BTIG Research upped their price objective on Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Scotiabank increased their price objective on Castle Biosciences from $37.00 to $44.00 and gave the stock a “sector outperform” rating in a research note on Wednesday, November 6th. Stephens reissued an “overweight” rating and set a $41.00 price objective on shares of Castle Biosciences in a report on Thursday, January 2nd. Canaccord Genuity Group upped their target price on shares of Castle Biosciences from $35.00 to $42.00 and gave the stock a “buy” rating in a report on Tuesday, October 29th. Finally, KeyCorp lifted their price target on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $40.29.

Insider Transactions at Castle Biosciences

In other news, Director Daniel Bradbury sold 7,867 shares of Castle Biosciences stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $29.14, for a total transaction of $229,244.38. Following the completion of the sale, the director now owns 1,425 shares in the company, valued at $41,524.50. The trade was a 84.66 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Derek J. Maetzold sold 2,715 shares of the stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $29.62, for a total transaction of $80,418.30. Following the completion of the transaction, the insider now owns 82,047 shares in the company, valued at $2,430,232.14. This represents a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 36,292 shares of company stock worth $1,099,755 over the last 90 days. 7.20% of the stock is owned by insiders.

Castle Biosciences Stock Down 7.5 %

Shares of NASDAQ:CSTL opened at $30.25 on Friday. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. The firm has a market cap of $847.21 million, a P/E ratio of 151.26 and a beta of 0.92. Castle Biosciences, Inc. has a 12 month low of $16.97 and a 12 month high of $35.84. The company’s 50-day moving average price is $29.81 and its two-hundred day moving average price is $27.87.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.06) by $0.14. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.47%. The business had revenue of $85.78 million for the quarter, compared to analysts’ expectations of $78.55 million. During the same period in the prior year, the firm earned ($0.26) earnings per share. As a group, research analysts forecast that Castle Biosciences, Inc. will post 0.34 EPS for the current fiscal year.

Castle Biosciences Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.